Elacestrant is a novel estrogen receptor antagonist that is primarily used to treat specific types of breast cancer. It inhibits the growth of tumor cells by targeting the ERα receptor and is suitable for patients with advanced or metastatic breast cancer who are ER-positive, HER2-negative and carry ESR1 mutations.
Indications for Elacestrant
Erastratran is a targeted therapy for selected breast cancer patients with well-defined and targeted indications. The specifics of its indications are discussed in detail below.
Treatment of ER-positive breast cancer
Eralastrant is mainly used to treat estrogen receptor (ER)-positive breast cancer patients. ER positivity means that the growth of tumor cells is dependent on estrogen stimulation, and alastran blocks this signaling pathway by antagonizing estrogen receptors, thereby inhibiting tumor progression. Clinical trials have shown that Elacestrant has shown significant efficacy in ER-positive patients.
Use in patients with ESR1 mutations
For breast cancer patients with ESR1 mutations, alalastran shows a unique advantage. ESR1 mutations may lead to resistance to traditional endocrine therapy, and Elacestrant can effectively overcome this resistance, providing a new treatment option for these patients. The study data showed that alalastrant significantly prolonged progression-free survival in patients with ESR1 mutations.
The indication of Elacestrant is focused on ER-positive breast cancer patients with ESR1 mutations, and its unique mechanism brings hope to patients who have failed traditional treatments. Let's look at who is a good candidate for this medication.
Who is Elacestrant suitable for?
Erastatran is indicated for a population with well-defined characteristics, including patients of specific gender, age, and disease status. The following is a detailed analysis of the conditions under which it applies.
Postmenopausal female patients
Erastratran is mainly indicated for postmenopausal female breast cancer patients. Postmenopausal women have low levels of estrogen in their bodies, but tumors may still rely on the ER signaling pathway to grow. Erastratran can effectively inhibit tumor progression by antagonizing the ER receptor, which has become an important treatment option for such patients.
Adult male patients
Although breast cancer is rare in men, Elacestrant is also indicated in adult men who are ER-positive and HER2-negative. Male breast cancer patients are often sensitive to endocrine therapy, and Elacestrant offers a new treatment, especially after traditional treatments have failed.
Erastratrant is indicated in postmenopausal women and adult men, but its use should be strictly clinically indicated. Next, we will discuss which groups of people should avoid this drug.
Who is the prohibited group of Elacestrant?
Erastatran is not suitable for all breast cancer patients, and certain populations should be contraindicated or used with caution. The following is a detailed analysis of the conditions under which it is disabled.
Pregnant and lactating women
Erastratran is potentially harmful to the fetus and should be contraindicated by pregnant women. Animal experiments have shown that Elacestrant may cause abnormal embryonic development. Breastfeeding women should also avoid using the drug, which can cause adverse effects on the baby through breast milk.
Patients with severe hepatic impairment
Erastratran should be contraindicated in patients with severe hepatic impairment (Child-Pugh class C). Drug metabolism is dependent on liver function, and hepatic insufficiency may lead to drug accumulation, increasing the risk of toxicity. Patients with moderate hepatic impairment should adjust the dose and use it under the guidance of a physician.
Erastratrant is prohibited in pregnant and lactating women, and patients with severe hepatic impairment, and these restrictions reflect the need for safe drug use. By understanding the indications, suitable populations, and contraindicated populations, patients and physicians can use the drug more rationally.
